Mitochondria and drugs

Advances in Experimental Medicine and Biology

Volumn 942, Issue , 2012, Pages 329-346

  Scatena, Roberto ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Apoptosis; Cancer metabolism; Degenerative diseases; Drug effects; Free radicals; Mitochondrial diseases; Nitric oxide; Toxic effects

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIOXIDANT; ASCORBIC ACID; CROMAKALIM; CYTOCHROME C OXIDASE INHIBITOR; DIAZOXIDE; ENZYME INHIBITOR; FIBRIC ACID DERIVATIVE; GLITAZONE DERIVATIVE; MENADIONE; MINOXIDIL SULFATE; MITOCHONDRIAL CHANNEL MODULATOR; MITOCHONDRIAL DNA; NICORANDIL; NONSTEROID ANTIINFLAMMATORY AGENT; PHYTOMENADIONE; PINACIDIL; POTASSIUM CHANNEL STIMULATING AGENT; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE) INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SUCCINATE DEHYDROGENASE (UBIQUINONE) INHIBITOR; UBIDECARENONE; UBIQUINOL CYTOCHROME C REDUCTASE INHIBITOR; UNCLASSIFIED DRUG; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACUTE LIVER FAILURE; ALZHEIMER DISEASE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELLULAR PARAMETERS; COMPLEX III DEFICIENCY; DEGENERATIVE DISEASE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; ENZYME INHIBITION; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; ION TRANSPORT; MEMBRANE CHANNEL; METABOLIC REGULATION; MITOCHONDRIAL CHANNEL; MITOCHONDRIAL ELECTRON TRANSPORT CHAIN; MITOCHONDRIAL FUNCTION; MITOCHONDRIAL PERMEABILITY; MITOCHONDRIAL RESPIRATION; MITOCHONDRIAL TOXICITY; MITOCHONDRION; MITOCHONDRION STRUCTURE; OXIDATIVE PHOSPHORYLATION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RESPIRATORY CHAIN; RHABDOMYOLYSIS;

ELECTRON TRANSPORT; HUMANS; MITOCHONDRIA; OXIDATIVE PHOSPHORYLATION; PHARMACEUTICAL PREPARATIONS;

EID: 84859901759     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-94-007-2869-1_15     Document Type: Article

References (118)

1. Alvarez FG, Guntupalli KK (1995) Isoniazid overdose: four case reports and review of the literature. Intensive Care Med 21:641-644
2. Bayley JP, Devilee P, Taschner PE (2005) The SDH mutation database: an online resource for succinate dehydrogenase sequence variants involved in pheochromocytoma, paragangliomaand mitochondrial complex II deficiency. BMC Med Genet 6:39
3. Benard G, Bellance N, Jose C et al (2010) Multi-site control and regulation of mitochondrial energy production. Biochim Biophys Acta 1797:698-709
4. Bouchier-Hayes L, Lartigue L, Newmeyer DD (2005) Mitochondria: pharmacological manipulation of cell death. J Clin Invest 10:2640-2647
5. Brandon M, Baldi P, Wallace DC (2006) Mitochondrial mutations in cancer. Oncogene 25:4647-4662
6. Brown GC, Borutaite V (2004) Inhibition of mitochondrial respiratory complex I by nitric oxide, peroxynitrite and S-nitrosothiols. Biochim Biophys Acta 1658:44-49
7. Brunmair B, Lest A, Staniek K (2004a) Fenofibrate impairs rat mitochondrial function by inhibition of respiratory complex I. J Pharmacol Exp Ther 311:109-114
8. Brunmair B, Staniek K, Gras F (2004b) Thiazolidinediones, like metformin, inhibit respiratory complex I: acommon mechanism contributing to their antidiabetic actions? Diabetes 53:1052-1059
9. Callahan J, Kopecek J (2006) Semitelechelic HPMA copolymers functionalized with triphenylphosphonium as drug carriers for membrane transduction and mitochondrial localization. Biomacromolecules 7:2347-2356
10. Cardoso AR, Queliconi BB, Kowaltowski AJ (2010) Mitochondrial ion transport pathways: role in metabolic diseases. Biochim Biophys Acta 1797:832-838
11. Carreras MC, Franco MC, Peralta JG, Poderoso JJ (2004) Nitric oxide, complex I, and the modulation of mitochondrial reactive species in biology and disease. Mol Aspects Med 25:125-139
12. Christians U, Gottschalk S, Miljus J (2004) Alterations in glucose metabolism by cyclosporine in rat brain slices link to oxidative stress: interactions with mTOR inhibitors. Br J Pharmacol 143:388-396
13. Czarnecka AM, Czarnecki JS, Kukwa W (2010) Molecular oncology focus-is carcinogenesis amitochondriopathy? J Biomed Sci 25:17-31
14. Dalgaard LT (2011) Genetic variance in uncoupling protein 2 in relation to obesity, type 2 diabetes, and related metabolic traits: focus on the functional-866G>A promoter variant (rs659366). J Obes 2011:340241
15. Davidson MH, Clark JA, Glass LM, Kanumalla A (2006) Statin safety: an appraisal from the adverse event reporting system. Am J Cardiol 97:32C-43C
16. de Moura MB, dos Santos LS, Van Houten B (2010) Mitochondrial dysfunction in neurodegenerative diseases and cancer. Environ Mol Mutagen 51:391-405
17. De Souza CT, Araújo EP, Stoppiglia LF (2007) Inhibition of UCP2 expression reverses diet-induced diabetes mellitus by effects on both insulin secretion and action. FASEB J 21:1153-1163
18. Degli Esposti M (1998) Inhibitors of NADH-ubiquinone reductase: an overview. Biochim Biophys Acta 1364: 222-235
19. Deschamps D, DeBeco V, Fisch C et al (1994) Inhibition by perhexiline of oxidative phosphorylation and the betaoxidation of fatty acids: possible role in pseudoalcoholic liver lesions. Hepatology 19:948-961
20. Detmer SA, Chan DC (2007) Functions and dysfunctions of mitochondrial dynamics. Nat Rev Mol Cell Biol 8:870-879
21. Dias N, Bailly C (2005) Drugs targeting mitochondrial functions to control tumor cell growth. Biochem Pharmacol 70:1-12
22. Don AS, Hogg PJ (2004) Mitochondriaas cancer drug targets. Trends Mol Med 10:372-378
23. Drose S, Brandt U, Hanley PJ (2006) K+-independent actions of diazoxide question the role of inner membrane KATP channels in mitochondrial cytoprotective signaling. J Biol Chem 281:23733-23739
24. Du H, Yan SS (2010) Mitochondrial medicine for neurodegenerative diseases. Int J Biochem Cell Biol 42:560-572
25. Duchen MR (2004) Mitochondriain health and disease: perspectives on anew mitochondrial biology. Mol Aspects Med 25:365-451
26. Eguchi Y, Takahari Y, Higashijima N (2009) Nicorandil attenuates FeCl(3)-induced thrombus formation through the inhibition of reactive oxygen species production. Circ J 73:554-561
27. Ernster L (1984) Bioenergetics. Elsevier Science Publishers, Amsterdam, The Netherlands
28. Fahn S, Sulzer D (2005) Neurodegeneration and neuroprotection in Parkinson disease. NeuroRx 1:139-154
29. Fau D, Eugene D, Berson A (1994) Toxicity of the antiandrogen flutamide in isolated rat hepatocytes. J Pharmacol Exp Ther 269:954-962
30. Fernandes MA, Santos MS, Moreno AJ (2004) Glibenclamide interferes with mitochondrial bioenergetics by inducing changes on membrane ion permeability. J Biochem Mol Toxicol 18:162-169
31. Figueroa S, Oset-Gasque MJ, Arce C (2006) Mitochondrial involvement in nitric oxide-induced cellular death in cortical neurons in culture. J Neurosci Res 83:441-449
32. Filser M, Werner S (1988) Pethidine analogues, anovel class of potent inhibitors of mitochondrial NADH: ubiquinone reductase. Biochem Pharmacol 37:2551-2558
33. Fleischer S and Parcker L (1979) Biomembranes, Part F: bioenergetics: oxidative phosphorylation, Methods in enzymol. Academic Press, New York
34. Foody JM, Rathore SS, Galusha D (2006) Hydroxymethylglutaryl-CoA reductase inhibitors in older persons with acute myocardial infarction: evidence for an age-statin interaction. J Am Geriatr Soc 3:421-430
35. Frantz MC, Wipf P (2010) Mitochondriaas atarget in treatment. Environ Mol Mutagen 51:462-475
36. Fromenty B, Fisch C, Berson A (1990) Dual effect of amiodarone on mitochondrial respiration. Initial protonophoric uncoupling effect followed by inhibition of the respiratory chain at the levels of complex I and complex II. J Pharmacol Exp Ther 255:1377-1384
37. Fulda S, Galluzzi L, Kroemer G (2010) Targeting mitochondriafor cancer therapy. Nat Rev Drug Discov 9:447-464
38. Giorgi C, Agnoletto C, Bononi A et al (2011) Mitochondrial calcium homeostasis as potential target for mitochondrial medicine. Mitochondrion (in press)
39. Gottlieb E, Tomlinson IP (2005) Mitochondrial tumour suppressors: agenetic and biochemical update. Nat Rev Cancer 5:857-866
40. Haendeler J, Dröse S, Büchner N et al (2009) Mitochondrial telomerase reverse transcriptase binds to and protects mitochondrial DNA and function from damage. Arterioscler Thromb Vasc Biol 29:929-935
41. Hamm-Alvarez S, Cadenas E (2009) Mitochondrial medicine and therapeutics, Part II. Preface. Adv Drug Deliv Rev 61:1233
42. Harold F (1986) The Vital Force: A Study of Bioenergetics, W.H. Freeman & Co., New York
43. Harper JA, Dickinson K, Brand MD (2001) Mitochondrial uncoupling as atarget for drug development for the treatment of obesity. Obes Rev 2:255-265
44. Hatefi Y (1985) The mitochondrial electron transport and oxidative phosphorylation system. Annu Rev Biochem 54:1015-1069
45. Ho WP, Chen TL, Chiu WT et al (2005) Nitric oxide induces osteoblast apoptosis through amitochondria-dependent pathway. Ann NY Acad Sci 1042:460-470
46. Hoye AT, Davoren JE, Wipf P et al (2008) Targeting mitochondria. Acc Chem Res 41:87-97
47. Indig GL, Anderson GS, Nichols MG et al (2000) Effect of molecular structure on the performance of triarylmethane dyes as therapeutic agents for photochemical purging of autologous bone marrow grafts from residual tumor cells. J Pharm Sci 89:88-99
48. Ishii T, Yasuda K, Akatsuka A et al (2005) A mutation in the SDHC gene of complex II increases oxidative stress, resulting in apoptosis and tumorigenesis. Cancer Res 65:203-209
49. Jaeschke H (2007) Troglitazone hepatotoxicity: are we getting closer to understanding idiosyncratic liver injury? Toxicol Sci 97:1-3
50. Kooncumchoo P, SharmaS, Porter J et al (2006) Coenzyme Q(10)provides neuroprotection in iron-induced apoptosis in dopaminergic neurons. J Mol Neurosci 28:125-141
51. Krahenbuhl S (2001) Mitochondria: important target for drug toxicity? J Hepatol 34:334-336
52. Krueger MJ, Singer TP, Casida JE, Ramsay RR (1990) Evidence that the blockade of mitochondrial respiration by the neurotoxin 1-methyl-4- phenylpyridinium (MPP+) involves binding at the same site as the respiratory inhibitor, rotenone. Biochem Biophys Res Commun 169:123-128
53. Leite AZ, Sipahi AM, Damiao AO et al (2001) Protective effect of metronidazole on uncoupling mitochondrial oxidative phosphorylation induced by NSAID: anew mechanism. Gut 2:163-167
54. Lemarie A, Grimm S (2011) Mitochondrial respiratory chain complexes: apoptosis sensors mutated in cancer? Oncogene 30:3985-4003
55. Lenaz G, Baracca A, Fato R et al (2006) New insights into structure and function of mitochondriaand their role in aging and disease. Antioxid Redox Signal 8:417-437
56. Lewis W, Day BJ, Copeland WC (2003) Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective. Nat Rev Drug Discov 10:812-822
57. Lewis W, Kohler JJ, Hosseini SH et al (2006) Antiretroviral nucleosides, deoxynucleotide carrier and mitochondrial DNA: evidence supporting the DNA pol gammahypothesis. AIDS 5:675-684
58. Lopez-Soriano J, Chiellini C, Maffei M et al (2006) Roles of skeletal muscle and peroxisome proliferator-activated receptors in the development and treatment of obesity. Endocr Rev 27:318-329
59. Lund KC, Wallace KB (2004) Direct, DNA pol-gamma-independent effects of nucleoside reverse transcriptase inhibitors on mitochondrial bioenergetics. Cardiovasc Toxicol 4:217-228
60. McKee EE, Ferguson M, Bentley AT, Marks TA (2006) Inhibition of mammalian mitochondrial protein synthesis by oxazolidinones. Antimicrob Agents Chemother 50:2042-2049
61. Minamiyama Y, Ichikawa H, Takemura S et al (2010) Generation of reactive oxygen species in sperms of rats as an earlier marker for evaluating the toxicity of endocrine-disrupting chemicals. Free Radic Res 44:1398-1406
62. Miyoshi H (1998) Structure-activity relationships of some complex I inhibitors. Biochim Biophys Acta 1364:236-244
63. Moncada S, Erusalimsky JD (2002) Does nitric oxide modulate mitochondrial energy generation and apoptosis? Nat Rev Mol Cell Biol 3:214-219
64. Moreno-Sanchez R, Bravo C, Vasquez C et al (1999) Inhibition and uncoupling of oxidative phosphorylation by nonsteroidal anti-inflammatory drugs: study in mitochondria, submitochondrial particles, cells, and whole heart. Biochem Pharmacol 57:743-752
65. Morikawa N, Nakagawa-Hattori Y, Mizuno Y (1996) Effect of dopamine, dimethoxyphenylethylamine, papaverine, and related compounds on mitochondrial respiration and complex I activity. J Neurochem 66:1174-1181
66. Murphy MP, Smith RAJ (2000) Drug delivery to mitochondria: the key to mitochondrial medicine. Adv Drug Deliv Rev 41:235-250
67. Nadanaciva S, Will Y (2011) New insights in drug-induced mitochondrial toxicity. Curr Pharm Des 17:2100-2112
68. Nulton-Persson AC, Szweda LI, Sadek HA (2004) Inhibition of cardiac mitochondrial respiration by salicylic acid and acetylsalicylate. J Cardiovasc Pharmacol 44:591-595
69. ORourke B (2000) Myocardial K ATP channels in preconditioning. Circ Res 87:845-855
70. Oliveira PJ (2011) Mitochondriaas adrug target in health and disease. Curr Drug Targets 12:761
71. Ong MM, Latchoumycandane C, Boelsterli UA (2007) Troglitazone-induced hepatic necrosis in an animal model of silent genetic mitochondrial abnormalities. Toxicol Sci 97:205-213
72. Ooi EM, Watts GF, Sprecher DL et al (2011) Mechanism of action of aPeroxisome Proliferator-Activated Receptor (PPAR)-deltaagonist on lipoprotein metabolism in dyslipidemic subjects with central obesity. J Clin Endocrinol Metab 96:E1568-E1576
73. Perumal SS, Shanthi P, Sachdanandam P (2005) Therapeutic effect of tamoxifen and energy-modulating vitamins on carbohydrate-metabolizing enzymes in breast cancer. Cancer Chemother Pharmacol 56:105-114
74. Pessayre D (2007) Role of mitochondriain non-alcoholic fatty liver disease. J Gastroenterol Hepatol 22:S20-S27
75. Pollard PJ, Brière JJ, Alam NA et al (2005) Accumulation of Krebs cycle intermediates and over-expression of HIF1 a in tumours which result from germline FH and SDH mutations. Hum Mol Genet 14:2231-2239
76. Price KE, Pearce RE, Garg UC et al (2011) Effects of valproic acid on organic acid metabolism in children: ametabolic profiling study. Clin Pharmacol Ther 89:867-874
77. Radi R, Cassina A, Hodara R (2002) Nitric oxide and peroxynitrite interactions with mitochondria. Biol Chem 383:401-409
78. Ralph SJ, Rodríguez-Enríquez S, Neuzil J, Moreno-Sánchez R (2010) Bioenergetic pathways in tumor mitochondriaas targets for cancer therapy and the importance of the ROS-induced apoptotic trigger. Mol Aspects Med 31:29-59
79. Raza H, John A, Benedict S (2011) Acetylsalicylic acid-induced oxidative stress, cell cycle arrest, apoptosis and mitochondrial dysfunction in human hepatomaHepG2 cells. Eur J Pharmacol 668:15-24
80. Renner K, Amberger A, Konwalinka G et al (2003) Changes of mitochondrial respiration, mitochondrial content and cell size after induction of apoptosis in leukemiacells. Biochim Biophys Acta 1642:115-123
81. Richard D, Picard F (2011) Brown fat biology and thermogenesis. Front Biosci 16:1233-1260
82. Rohlena J, Dong LF, Ralph SJ, Neuzil J (2011) Anticancer drugs targeting the mitochondrial electron transport chain. Antioxid Redox Signal 15:2951-74
83. Russmann S, Jetter A, Kullak-Ublick GA (2010) Pharmacogenetics of drug-induced liver injury. Hepatology 52: 748-761
84. Scarpignato C, Hunt RH (2010) Nonsteroidal antiinflammatory drug-related injury to the gastrointestinal tract: clinical picture, pathogenesis, and prevention. Gastroenterol Clin North Am 39:433-464
85. Scatena R, Bottoni P, Vincenzoni F et al (2003) Bezafibrate induces amitochondrial derangement in human cell lines. Intriguing effects for aperoxisome proliferator. Chem Res Toxicol 16:1440-1447
86. Scatena R, Bottoni P, Martorana GE et al (2004a) Mitochondrial respiratory chain dysfunction, anon receptor-mediated effect of synthetic PPAR-ligands. Biochemical and pharmacological implications. Biochem Biophys Res Commun 319:967-973
87. Scatena R, Martorana GE, Bottoni P, Giardina B (2004b) Mitochondrial dysfunction by synthetic ligands of peroxisome proliferator activated receptors (PPARs). IUBMB Life 56:477-482
88. Scatena R, Bottoni P, Martorana GE, Giardina B (2005) Nitric oxide donor drugs: an update on pathophysiology and therapeutic potential. Expert Opin Investig Drugs 14:835-846
89. Scatena R, Bottoni P, Botta G et al (2007a) The role of mitochondriain pharmacotoxicology: areevaluation of an old, newly emerging topic. Am J Physiol Cell Physiol 293:C12-C21
90. Scatena R, Bottoni P, Martorana GE et al (2007b) Mitochondria, ciglitazone and liver: aneglected interaction in biochemical pharmacology. Eur J Pharmacol 567:50-58
91. Scatena R, Bottoni P, Giardina B (2008) Mitochondria, PPARs, and cancer: is receptor-independent action of PPAR agonists akey? PPAR Res 2008:256251
92. Scatena R, Bottoni P, Pontoglio A, Giardina B (2010) Pharmacological modulation of nitric oxide release: new pharmacological perspectives, potential benefits and risks. Curr Med Chem 17:61-73
93. Scatena R, Bottoni P, Pontoglio A, Giardina B (2011) Cancer stem cells: the development of new cancer therapeutics. Expert Opin Biol Ther 11:875-892
94. Schaars CF, Stalenhoef AF (2008) Effects of ubiquinone (coenzyme Q10) on myopathy in statin users. Curr Opin Lipidol 19:553-557
95. Schaefer WH, Lawrence JW, Loughlin AF et al (2004) Evaluation of ubiquinone concentration and mitochondrial function relative to cerivastatin-induced skeletal myopathy in rats. Toxicol Appl Pharmacol 194:10-23
96. Shneyvays V, Leshem D, Shmist Y et al (2005) Effects of menadione and its derivative on cultured cardiomyocytes with mitochondrial disorders. J Mol Cell Cardiol 1:149-158
97. Singer TP, Gutman M (1971) The DPNH dehydrogenase of the mitochondrial respiratory chain. Adv Enzymol Relat Areas Mol Biol 34:79-153
98. Skalska J, Debska G, Kunz WS, Szewczyk A (2005) Antidiabetic sulphonylureas activate mitochondrial permeability transition in rat skeletal muscle. Br J Pharmacol 145:785-791
99. Solaini G, Sgarbi G, Baracca A (2011) Oxidative phosphorylation in cancer cells. Biochim Biophys Acta 1807:534-542
100. Senthilnathan P, Padmavathi R, Magesh V, Sakthisekaran D (2006) Modulation of TCA cycle enzymes and electron transport chain systems in experimental lung cancer Life Sci 78:1010-1014
101. Subramanyam B, Rollema H, Woolf T, Castagnoli N Jr (1990) Identification of apotentially neurotoxic pyridinium metabolite of haloperidol in rats. Biochem Biophys Res Commun 166:238-244
102. Suski J, Lebiedzinska M, Machado NG et al (2011) Mitochondrial tolerance to drugs and toxic agents in ageing and disease. Curr Drug Targets 12:827-849
103. Szewczyk A, Wojtczak L (2002) Mitochondriaas apharmacological target. Pharmacol Rev 54:101-127
104. Szewczyk A, Kajma A, Malinska D et al (2010) Pharmacology of mitochondrial potassium channels: dark side of the field. FEBS Lett 584:2063-2069
105. Tafazoli S, Mashregi M, OBrien PJ (2008) Role of hydrazine in isoniazid-induced hepatotoxicity in ahepatocyte inflammation model. Toxicol Appl Pharmacol 229:94-101
106. Takahashi A, Ohtani N, Yamakoshi K et al (2006) Mitogenic signalling and the p16INK4a-Rb pathway cooperate to enforce irreversible cellular senescence. Nat Cell Biol 8:1291-1297
107. Veitch K, Hue L (1994) Flunarizine and cinnarizine inhibit mitochondrial complexes I and II: possible implication for parkinsonism. Mol Pharmacol 45:158-163
108. Vickers AE (2009) Characterization of hepatic mitochondrial injury induced by fatty acid oxidation inhibitors. Toxicol Pathol 37:78-88
109. Vickers AEM, Bentley P, Fisher RL (2006) Consequences of mitochondrial injury induced by pharmaceutical fatty acid oxidation inhibitors is characterized in human and rat liver slices. Toxicol In Vitro 20:1173-1182
110. Wagner BK, Kitami T, Gilbert TJ et al (2008) Large-scale chemical dissection of mitochondrial function. Nat Biotechnol 26:343-351
111. Wallace KB (2003) Doxorubicin-induced cardiac mitochondrionopathy. Pharmacol Toxicol 93:105-115
112. Wallace KB, Starkov AA (2000) Mitochondrial targets of drugs toxicity. Annu Rev Pharmacol Toxicol 40:353-388
113. Wang S, Cone J, Liu Y (2001) Dual roles of mitochondrial KATP channels in diazoxide-mediated protection in isolated rabbit hearts. Am J Physiol 280:H246-H256
114. Wang YX, Lee CH, Tiep S et al (2003) Peroxisome-proliferator-activated receptor deltaactivates fat metabolism to prevent obesity. Cell 113:159-170
115. White KL, Margot NA, Ly JK et al (2005) A combination of decreased NRTI incorporation and decreased excision determines he resistance profile of HIV-1 K65R RT. AIDS 19:1751-1760
116. Woo MN, Jeon SM, Shin YC et al (2009) Anti-obese property of fucoxanthin is partly mediated by altering lipid-regulating enzymes and uncoupling proteins of visceral adipose tissue in mice. Mol Nutr Food Res 53:1603-1611
117. Yip KW, Ito E, Mao X et al (2006) Potential use of alexidine dihydrochloride as an apoptosis-promoting anticancer agent. Mol Cancer Ther 5:2234-2240
118. Zhu X (2010) Mitochondrial dysfunction: mitochondrial diseases and pathways with afocus on neurodegeneration. Preface. Biochim Biophys Acta 1802:1